EBET-1055

Cat. No.:	HY-161346
Molecular Formula:	$C_{51}H_{54}N_8O_9$
Molecular Weight:	923.02
Target:	ADC Cytotoxin; Epigenetic Reader Domain
Pathway:	Antibody-drug Conjugate/ADC Related; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EBET-1055 is a bromodomain and extra-terminal (BET) protein degrader (EBET) composed of a BET inhibitor (EBET-590, HY-161387), an E3 ubiquitin ligase ligand and connectors. EBET-1055 effectively inhibits the growth of pancreatic ductal adenocarcinoma (PDAC). EBET-1055 also simultaneously modulates cancer-associated fibroblast (CAF) activity, upregulating all reporter gene activities in organoid co-cultures[1].
In Vitro	EBET-1055 (1 nM, 10 nM; 2 d) inhibits CAF-induced IL-6 and LIF secretion when co-cultured with mouse CAF and PC-3 or PC-42 cancer cells[1].br /EBET-1055 has potential anti-inflammatory or anti-fibrotic activity. STAT3 signaling mediates the inflammatory CAF (iCAF) phenotype, and SMAD signaling mediates the myofibroblast CAF (myCAF) phenotype; and EBET-1055 (1-100 nM; 24 h) may inhibit the interaction of BRD proteins with STAT3 and SMAD3 It inhibits myofibroblast differentiation and reduces the phosphorylation levels of SMAD3 and STAT3 in mouse fibrotic kidneys[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA